Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | EBP | Q15125 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 2/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21394848 | 0.80 | S1PR1 (0.46) | TP53TSHRLMNACYP19A1CYP1A2 | |
| SCHEMBL270340 | 0.80 | ALDH1A1 (0.62) | KIF11TSHRLMNAHTTALDH1A1 | |
| SCHEMBL21394315 | 0.79 | CYP3A4 (0.41) | LMNAALDH1A1CYP19A1CYP1A2CYP3A4 | |
| SCHEMBL9587694 | 0.77 | KIF11 (0.55) | KIF11SIGMAR1LMNAHTTALDH1A1 | |
| SCHEMBL9296848 | 0.77 | TSHR (0.55) | TP53TSHREBPSIGMAR1LMNA | |
| SCHEMBL8323180 | 0.77 | TSHR (0.55) | TP53TSHREBPSIGMAR1LMNA | |
| SCHEMBL10667108 | 0.77 | TSHR (0.55) | TP53TSHREBPSIGMAR1LMNA | |
| SCHEMBL8678455 | 0.77 | TSHR (0.55) | TP53TSHREBPSIGMAR1LMNA | |
| SCHEMBL8840559 | 0.77 | TSHR (0.55) | TP53TSHREBPSIGMAR1ACACB | |
| SCHEMBL8967452 | 0.77 | TSHR (0.55) | TP53TSHREBPSIGMAR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250298383-A1 | INTELLIGENT BUILDING MANAGEMENT SYSTEMS | SmithGroup Companies, Inc. | 2025-09-25 | — | — | US | disclosed |
| US-12276951-B2 | Intelligent building management systems | SmithGroup Companies, Inc. (US) | 2025-04-15 | — | — | US | disclosed |
| US-20230364178-A1 | Small Molecule Cancer Treatments that Cause Necrosis in Cancer Cells But Do Not Affect Normal Cells | UNIV NEW YORK STATE RES FOUND (US) | 2023-11-16 | — | — | US | disclosed |
| US-20220283553-A1 | INTELLIGENT BUILDING MANAGEMENT SYSTEMS | SmithGroup Companies, Inc. | 2022-09-08 | — | — | US | disclosed |
| CN-111511374-B | Carbon dioxide sustained release pack for skin and method for releasing carbon dioxide to skin | 三井化学株式会社 | 2022-05-17 | — | — | CN | disclosed |
| EP-0440608-A1 | ANTIFUNGAL CARBINOLS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-08-14 | — | — | EP | disclosed |
| WO-1989005801-A1 | ANTIFUNGAL CARBINOLS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-06-29 | — | — | WO | disclosed |
| EP-0321211-A1 | Antifungal carbinols | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364178-A1 | Small Molecule Cancer Treatments that Cause Necrosis in Cancer Cells But Do Not Affect Normal Cells | HMGB2, HMGB1, HMGB3 | KIF11 3588/4885TP53 10/4885TSHR 4733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.